Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHALIN vs INVERSINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors, blocking ganglionic transmission in both sympathetic and parasympathetic ganglia.
Hypertension (FDA-approved),Attention deficit hyperactivity disorder (ADHD) (off-label),Opioid withdrawal (off-label)
Management of moderately severe to severe essential hypertension,Unresponsive hypertension to other agents
500 mg orally once daily
Initial: 2.5 mg orally twice daily; increase by 2.5-5 mg every 2-3 days until blood pressure controlled; usual maintenance: 10-75 mg/day in 2-4 divided doses; max single dose: 25 mg; max daily dose: 200 mg.
Terminal half-life 12-15 hours (healthy adults); prolonged to 24-30 hours in renal impairment (Cr Cl <30 m L/min)
3-5 hours in patients with normal renal function; may be prolonged in renal impairment (up to 12-24 hours in severe cases).
Primarily hepatic via cytochrome P450 isoenzyme CYP2D6; metabolites are excreted renally.
Primarily hepatic metabolism (unknown specific enzymes); eliminated renally with unchanged drug and metabolites.
Renal excretion (70% unchanged); fecal/biliary (20%); metabolism (10%)
Primarily renal (about 90% as unchanged drug), with minor biliary/fecal elimination (<10%).
98% bound primarily to albumin
~50% bound to plasma proteins (mainly albumin).
0.3-0.5 L/kg; reflects limited extravascular distribution consistent with high protein binding
Approximately 1 L/kg, indicating extensive extravascular distribution.
Oral: 80-90% (first-pass metabolism ~10-20%); IM: 95-100%
Oral: 50-75% (due to first-pass metabolism).
e GFR 30-59 m L/min: 250 mg orally once daily; e GFR 15-29 m L/min: 125 mg orally once daily; e GFR <15 m L/min: 125 mg orally every 48 hours
GFR 30-60 m L/min: reduce dose by 50%; GFR 10-29 m L/min: reduce dose by 75%; GFR <10 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 250 mg orally once daily; Child-Pugh Class C: 125 mg orally once daily
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
10-15 mg/kg orally once daily, not to exceed 500 mg/day
Not recommended for pediatric use due to lack of safety and efficacy data.
Initiate at 250 mg orally once daily; titrate based on renal function
Start at 2.5 mg once daily; increase slowly; monitor for orthostatic hypotension and syncope.
Avoid abrupt discontinuation; rapid withdrawal can cause rebound hypertension, anxiety, and, in severe cases, hypertensive encephalopathy or stroke.
None.
May cause sedation, dizziness, and orthostatic hypotension. Use caution in patients with cerebrovascular or cardiovascular disease. Monitor blood pressure regularly. Do not administer with other alpha-2 agonists.
May cause orthostatic hypotension, syncope, and falls. Use with caution in patients with cerebrovascular insufficiency, renal impairment, or recent myocardial infarction. Discontinue if symptoms of paralytic ileus occur.
Hypersensitivity to ALPHALIN or any component; concurrent use with other alpha-2 adrenergic receptor agonists; severe bradycardia or heart block (unless paced).
Coronary insufficiency, recent myocardial infarction, pyloric stenosis, glaucoma, uremia, and patients receiving concurrent antihypertensive therapy with ganglionic blocking agents.
No specific food interactions documented. However, avoid alcohol for 24 hours post-administration due to additive hypotensive effects. Grapefruit juice may potentiate alpha-blocker effects; avoid concurrent use.
Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats) as mecamylamine may potentiate pressor effects. Limit alcohol consumption due to additive hypotensive effects. High-sodium foods may counteract antihypertensive effect; follow a low-sodium diet as recommended.
First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.
Category C. First trimester: No adequate human studies; animal studies show embryotoxicity. Second/third trimester: Potential for meconium ileus, neonatal hypotension. Avoid in pregnancy.
Contraindicated during breastfeeding due to high transfer into breast milk; M/P ratio > 1.5.
Excreted in breast milk. M/P ratio unknown. Discontinue breastfeeding due to potential for serious adverse effects in infant.
Dose reduction by 30-50% recommended in second and third trimesters due to increased clearance.
No established dosing guidelines for pregnancy; increased clearance suggests need for dose escalation, but contraindicated due to risks.
ALPHALIN is a high-potency alpha-blocker indicated for hypertensive emergencies. Administer as a slow IV bolus over 5 minutes to avoid severe hypotension. Monitor blood pressure every 2 minutes during infusion. Have intravenous fluids and vasopressors ready. Contraindicated in patients with known hypersensitivity, acute myocardial infarction, or history of orthostatic hypotension.
INVERSINE (mecamylamine) is a noncompetitive nicotinic acetylcholine receptor antagonist used primarily for its ganglionic blocking effects in severe hypertension. Due to its narrow therapeutic index and significant side effects including orthostatic hypotension, constipation, and urinary retention, it is rarely used today. Monitor for paralytic ileus and bladder distention. Dosage must be titrated carefully based on standing blood pressure. Contraindicated in patients with coronary insufficiency, pyloric stenosis, or recent myocardial infarction.
This medication is given intravenously in a hospital setting only.,You will have continuous blood pressure monitoring during administration.,Report any dizziness, chest pain, or difficulty breathing immediately.,After treatment, rise slowly from sitting or lying to prevent fainting.,Avoid alcohol for 24 hours after treatment to prevent blood pressure drop.
Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Rise slowly from sitting or lying positions to avoid dizziness from low blood pressure.,Report any constipation, difficulty urinating, or blurred vision to your healthcare provider immediately.,Avoid alcohol and other medications that lower blood pressure without medical advice.,Do not drive or operate heavy machinery if you experience dizziness or blurred vision.,Maintain adequate fluid intake unless otherwise directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHALIN vs INVERSINE, answered by our medical review team.
ALPHALIN is a Vitamin A Supplement that works by ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.. INVERSINE is a Ganglionic Blocker Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors, blocking ganglionic transmission in both sympathetic and parasympathetic ganglia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHALIN and INVERSINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHALIN is: 500 mg orally once daily. The standard adult dose of INVERSINE is: Initial: 2.5 mg orally twice daily; increase by 2.5-5 mg every 2-3 days until blood pressure controlled; usual maintenance: 10-75 mg/day in 2-4 divided doses; max single dose: 25 mg; max daily dose: 200 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHALIN and INVERSINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHALIN is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.. INVERSINE is classified as Category C. Category C. First trimester: No adequate human studies; animal studies show embryotoxicity. Second/third trimester: Potential for meconium ileus, neonatal hypotension. Avoid in pre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.